摘要
CONSPECTUS:Insulin replacement therapy is an essential and effective treatment strategy for controlling the blood glucose level(BGL)of people without sufficient endogenous insulin production.However,insulin therapy faces challenges such as daily multiple injections and hypoglycemia risk arising from its narrow therapeutic index,which together leads to poor BGL control.Thus,glucose-responsive insulin delivery systems that can mimicβ-cell function are developed to improve BGL control and reduce injection frequency.Glucose-responsive materials-based insulin delivery systems are competent in tightly controlling the BGL with an additional benefit of reducing the hypoglycemia risk.
基金
supported by grants from National Key R&D Program of China(2021YFA0909900,2022YFE0202200)
Zhejiang University’s start-up packages,Kunpeng program from Zhejiang Province,Fundamental Research Funds for the Central Universities(2021FZZX001-46)
the Starry Night Science Fund at Shanghai Institute for Advanced Study of Zhejiang University(SN-ZJU-SIAS-009)
JDRF(grant no.2-SRA-2021-1064-M-B,2-SRA-2022-1159-M-B).
